Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
UNITE-ALS phase 2b study of Usnoflast in adults with amyotrophic lateral sclerosis
2025-522580-15-00Phase 2Authorised
- Sponsor
- Zydus Therapeutics
- Start
- Jul 2026
- Modality
- Small Molecules
- Countries
- 12
01
Overview
Phase 2, randomised, double-blind trial in amyotrophic lateral sclerosis (ALS) comparing Usnoflast with Placebo (2 arms). Primary endpoint: Change in disease progression from baseline through 36 weeks. Planned start Jul 2026; status: authorised.
02
Drugs
usnoflast
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on 2025-522580-15-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-522580-15-00.